Fujifilm's New Biologic Drug Plant Boosts US Manufacturing Capacity

Fujifilm's North Carolina Biologic Drug Facility

• 🏭 Inside one of the largest biologic drug factories in the US, Fujifilm's new North Carolina plant is a significant expansion.
• 🔬 The facility houses bioreactors, each capable of producing monoclonal antibodies and holding up to 20,000 liters.
• 🏗️ With 16 bioreactors planned by 2028, the plant will have the capacity to produce approximately 50 million doses of medicine annually.
• ⏱️ Fujifilm brought this factory from concept to reality in five years, a relatively quick turnaround for a project of this scale.

Supply Chain Agility and Flexibility

• 🎯 Fujifilm aims to provide its customers with flexibility to navigate supply chain disruptions, such as those caused by tariffs or events like COVID-19.
• 📈 The facility is designed to handle fluctuations in demand, ensuring supply chain agility.

US Pharmaceutical Manufacturing Expansion

• 🇺🇸 The US is seeing an increase in pharmaceutical manufacturing, with companies like Amgen expanding existing facilities and Genentech planning new ones.
• ⏳ Even relocating production to an existing facility can take two to three years, highlighting the complexity and time involved in building new capacity like Fujifilm's plant.

Global Investment Trends in Pharma Manufacturing

• 🌍 While investments in US and European pharma manufacturing were once split, companies are now increasingly investing in the US, with European investments scaling back.
• ⚠️ The US has a significant catch-up to play, as nearly half of injectable drug products sold in the US originate from Europe, compared to only 17% originating in the US.
• 📊 This trend underscores the critical importance of a country of origin for pharmaceutical products, especially concerning tariffs and supply chain security.